The Patent Finder

PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates

ADC Therapeutics S.A.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 11,690,918PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
In force
 · High confidence
UsedRemaining
ADC Therapeutics S.A.In forceHigh confidence
US 10,722,594PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
In force
 · High confidence
ADC Therapeutics S.A.In forceHigh confidence
US 9,919,056PYRROLOBENZODIAZEPINE-ANTI-CD22 Antibody Conjugates
Lapsed Mar 20, 2026 on the fee record
High confidence
ADC Therapeutics S.A.Lapsed Mar 20, 2026 on the fee recordHigh confidence
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by ADC Therapeutics S.A..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited